[
  {
    "ts": "2026-02-06T02:13:30+00:00",
    "headline": "Why Analysts See GSK (LSE:GSK) Differently As The Fair Value Story Starts To Shift",
    "summary": "The fair value estimate for GSK has been nudged to £18.83 from £18.73, a small move that reflects a tug of war between more optimistic price target hikes and ongoing caution around the company’s pipeline and execution. Supportive target changes, such as JPMorgan’s move to 1,500 GBp from 1,400 GBp even while staying cautious, sit alongside Underweight ratings that flag execution risk and limited upcoming readouts. Stay with this article to see how you can keep on top of these shifting signals...",
    "url": "https://finance.yahoo.com/news/why-analysts-see-gsk-lse-021330683.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "ab6ed439-17e2-3c0d-ad52-3f290c2c04cf",
      "content": {
        "id": "ab6ed439-17e2-3c0d-ad52-3f290c2c04cf",
        "contentType": "STORY",
        "title": "Why Analysts See GSK (LSE:GSK) Differently As The Fair Value Story Starts To Shift",
        "description": "",
        "summary": "The fair value estimate for GSK has been nudged to £18.83 from £18.73, a small move that reflects a tug of war between more optimistic price target hikes and ongoing caution around the company’s pipeline and execution. Supportive target changes, such as JPMorgan’s move to 1,500 GBp from 1,400 GBp even while staying cautious, sit alongside Underweight ratings that flag execution risk and limited upcoming readouts. Stay with this article to see how you can keep on top of these shifting signals...",
        "pubDate": "2026-02-06T02:13:30Z",
        "displayTime": "2026-02-06T02:13:30Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/a99782b24065c2e10ff5cc21f6727f48",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8CX3wjKCNbNdUwFzmm8p.w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/a99782b24065c2e10ff5cc21f6727f48.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/NSAOA6iLX_5mMzTqoEtpog--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/a99782b24065c2e10ff5cc21f6727f48.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/why-analysts-see-gsk-lse-021330683.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-analysts-see-gsk-lse-021330683.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GLAXF"
            },
            {
              "symbol": "GSK"
            },
            {
              "symbol": "JPM"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]